吉晟生7762.TW Overview
TW StockBiotech. & Medical
(No presentation for 7762)
吉晟生（7762）Overall Performance
吉晟生（7762）AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
Browsing restrictions can be lifted for a fee.
No related data records
The most recent financial report for 吉晟生 (7762) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7762's short-term business performance and financial health. For the latest updates on 7762's earnings releases, visit this page regularly.
At the end of the period, 吉晟生 (7762) held Total Cash and Cash Equivalents of 321.49M, accounting for 0.29 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 吉晟生 (7762) achieved the “three margins increasing” benchmark, with a gross margin of 50.05%%, operating margin of 3.59%%, and net margin of 9.62%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 7762's profit trajectory and future growth potential.
7762
吉晟生
-2.06%
(-0.02)